VCYT on Nasdaq

VERACYTE, INC.

American medical laboratories services company based in South San Francisco. Summary from the record

$45.27 up 1.76 (4.04%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 19, 2026.

Overview

Compare with CareDx, Inc, CASTLE BIOSCIENCES INC or Caris Life Sciences (United States), or pick any stock.

  • TickerVCYT on Nasdaq2
  • IndustryServices-Medical Laboratories2
  • HeadquartersSouth San Francisco, United States2
  • Incorporated inDE4
  • Business address6000 Shoreline Court, Suite 300, South San Francisco, Ca 940804
  • Filer categoryLarge accelerated filer4
  • Legal formCorporation2
  • LEI529900ESWZRHXOW27Z372
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o NATIONAL REGISTERED AGENTS, INC., 160 GREENTREE DR STE 101, 19904 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 41989982

See how the biggest companies compare on our leaderboards

At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic and predictive treatment decisions. Insights from these tests help patients avoid unnecessary procedures and interventions and accelerate time to appropriate treatment, thereby improving outcomes for patients across our global markets.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

70.1%Gross margin6
11.2%Operating margin6
12.8%Net margin6
16.0%Revenue growth, 20256
5.1%Return on equity6
$126.6MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Testing brought in 94% of the revenue VERACYTE, INC. broke down this way in fiscal 2025.

  1. Testing$493.2M694%up 18% from 2024
  2. Product$14.3M63%up 5% from 2024
  3. Biopharmaceutical And Other - Biopharmaceutical Revenue$6.5M61%down 9% from 2024
  4. Testing - Other$6.2M61%down 47% from 2024
  5. Biopharmaceutical And Other - Contract Manufacturing And Testing$3.1M61%down 48% from 2024
Products and services by year
Products and services202320242025
Testing$326.5M$419.0M$493.2M
Product$15.6M$13.7M$14.3M
Biopharmaceutical And Other - Biopharmaceutical Revenue$13.9M$7.1M$6.5M
Testing - Other$7.8M$11.8M$6.2M
Biopharmaceutical And Other - Contract Manufacturing And Testing$5.0M$6.0M$3.1M

Regions

United States brought in 96% of the revenue VERACYTE, INC. broke down this way in fiscal 2025.

  1. United States$496.6M696%up 17% from 2024
  2. Outside the United States$20.5M64%down 8% from 2024
Regions by year
Regions202320242025
United States$334.5M$423.5M$496.6M
Outside the United States$26.5M$22.2M$20.5M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development14¢$70.8M
  • Other costs73¢$378.1M
  • Income tax0¢$1.8M
  • Profit13¢$66.4M

Out of $517.1M in revenue.6

Where each dollar of operating cash went, fiscal 2025

  • Capital spending7¢$9.7M
  • Kept or used elsewhere93¢$126.6M

Out of $136.3M of cash from operations.6

Financial statements

Revenue789106$517.1M in 2025+330% since 2019
0$200.0M$400.0M$600.0M2019: $120.4M$120.4M20192020: $117.5M$117.5M2020−2%2021: $219.5M$219.5M2021+87%2022: $296.5M$296.5M2022+35%2023: $361.1M$361.1M2023+22%2024: $445.8M$445.8M2024+23%2025: $517.1M$517.1M2025+16%
Gross profit106$362.5M in 2025+106% since 2022
0$100.0M$200.0M$300.0M$400.0M2022: $175.7M$175.7M20222023: $229.7M$229.7M2023+31%2024: $298.1M$298.1M2024+30%2025: $362.5M$362.5M2025+22%
Operating income789106$57.8M in 2025
-$100.0M-$50.0M0$50.0M$100.0M2019: -$15.1M-$15.1M20192020: -$35.4M-$35.4M2020+134%2021: -$81.9M-$81.9M2021+131%2022: -$41.1M-$41.1M2022−50%2023: -$85.8M-$85.8M2023+109%2024: $16.1M$16.1M20242025: $57.8M$57.8M2025+258%
Net income789106$66.4M in 2025
-$100.0M-$50.0M0$50.0M$100.0M2019: -$12.6M-$12.6M20192020: -$34.9M-$34.9M2020+177%2021: -$75.6M-$75.6M2021+116%2022: -$36.6M-$36.6M2022−52%2023: -$74.4M-$74.4M2023+104%2024: $24.1M$24.1M20242025: $66.4M$66.4M2025+175%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-12-312024-12-312023-12-31
Total revenue$517.1M$445.8M$361.1M
Intangible asset amortization - cost of revenue$10.7M$11.6M$18.5M
Total cost of revenue$154.6M$147.6M$131.4M
Gross profit$362.5M$298.1M$229.7M
Research and development$70.8M$69.3M$57.3M
Selling and marketing$100.2M$95.4M$101.5M
General and administrative$110.8M$110.6M$86.2M
Impairment of assets$20.5M$3.4M$68.3M
Total operating expenses$304.8M$282.0M$315.5M
Income (loss) from operations$57.8M$16.1M-$85.8M
Other income, net$10.4M$9.6M$9.2M
Income (loss) before income taxes$68.2M$25.7M-$76.6M
Income tax provision (benefit)$1.8M$1.6M-$2.2M
Net income (loss)$66.4M$24.1M-$74.4M
Basic (in USD per share)$0.84$0.32-$1.02
Diluted (in USD per share)$0.82$0.31-$1.02
Basic (in shares)78.6M shares76.5M shares72.6M shares
Diluted (in shares)80.6M shares78.2M shares72.6M shares

Compare VERACYTE, INC. with another company

Leadership

Who has led VERACYTE, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Bonnie H. Anderson2013–2021
  2. Marc Stapley2021–now

Chair

  1. Bonnie H. Anderson2017–2022

President

  1. Bonnie H. Anderson2013–2016
  2. Tina Susan Nova2022

Chief financial officer

  1. Shelly D. Guyer2013–2016
  2. Rebecca Chambers2021–now
201520202025
Board members and other officers (25)

Former names

  • CALDEROME INCDec 6, 2006 to Feb 27, 20084

Timeline

  1. Jun 3, 2021New chief executive Marc Stapley becomes CEO14
  2. Oct 29, 2013New chief executive Bonnie H. Anderson becomes CEO15

Filings

502 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 40 major events, 277 insider forms, 53 large holders, 112 other. The latest 20:

  1. Sep 24, 2026144 EDGAR
  2. Sep 22, 20264 EDGAR
  3. Sep 21, 2026144 EDGAR
  4. Sep 16, 20264 EDGAR
  5. Sep 14, 2026144 EDGAR
  6. Sep 14, 20268-K EDGAR
  7. Sep 4, 20264 EDGAR
  8. Sep 4, 2026144 EDGAR
  9. Sep 4, 2026144 EDGAR
  10. Sep 4, 2026144 EDGAR
  11. Sep 4, 20264 EDGAR
  12. Sep 4, 20264 EDGAR
  13. Sep 4, 20264 EDGAR
  14. Sep 4, 20264 EDGAR
  15. Sep 4, 20264 EDGAR
  16. Sep 3, 20264 EDGAR
  17. Sep 1, 2026144 EDGAR
  18. Jul 31, 202610-Q EDGAR
  19. Jul 30, 20268-K EDGAR
  20. Jun 22, 20264 EDGAR

The 502 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

109 open-market trades by officers, directors and large owners since October 2021: 1 buys and 108 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 21, 2026Leite JohnGlobal Chief Commercial OffSale4,015$40.00$160.6KForm 4
Sep 14, 2026Holstein JensDirectorSale5,000$40.95$204.8KForm 4
Sep 4, 2026McGuire AnnieEVP, General CounselSale3,254$43.09$140.2KForm 4
Sep 4, 2026Chambers RebeccaChief Financial OfficerSale3,652$43.10$157.4KForm 4
Sep 4, 2026Febbo Phillip G.Chief Scientific & Med OfficerSale13,110$43.05$564.4KForm 4
Sep 1, 2026Bhanji MunaDirectorSale1,864$42.97$80.1KForm 4
Jun 18, 2026EASTHAM KARINDirectorSale3,729$52.89$197.2KForm 4
Jun 4, 2026Leite JohnGlobal Chief Commercial OffSale13,975$50.07$699.7KForm 4
Jun 4, 2026McGuire AnnieEVP, General CounselSale3,176$49.76$158.0KForm 4
Jun 4, 2026Chambers RebeccaChief Financial OfficerSale3,561$49.73$177.1KForm 4
Jun 4, 2026Stapley MarcChief Executive OfficerSale138,051$50.12$6.9MForm 4
May 22, 2026Wygant JonathanVP, Chief Accounting OfficerSale24,000$45.40$1.1MForm 4
May 20, 2026EPSTEIN ROBERT SDirectorSale10,000$44.01$440.1KForm 4
May 6, 2026McGuire AnnieEVP, General CounselSale10,204$39.02$398.2KForm 4
Mar 4, 2026Leite JohnGlobal Chief Commercial OffSale5,260$35.19$185.1KForm 4
Mar 4, 2026McGuire AnnieEVP, General CounselSale6,658$35.55$236.7KForm 4
Mar 4, 2026Chambers RebeccaChief Financial OfficerSale18,341$36.14$662.9KForm 4
Mar 4, 2026Stapley MarcChief Executive OfficerSale45,523$35.98$1.6MForm 4
Mar 2, 2026Febbo Phillip G.Chief Scientific & Med OfficerSale13,425$36.16$485.4KForm 4
Dec 16, 2025McGuire AnnieEVP, General CounselSale10,739$43.14$463.2KForm 4

All 109 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.13,486,437$792.1M0.0%+313,819
Fmr LLC7,702,746$452.4M0.0%−61,103
Artisan Partners Limited Partnership5,538,404$325.3M0.5%+42,034
Vanguard Portfolio Management LLC4,716,191$277.0M0.0%+271,461
State Street Corp4,698,128$276.0M0.0%−345,462
Vanguard Capital Management LLC3,593,922$211.1M0.0%+61,690
Dimensional Fund Advisors LP2,826,524$166.0M0.0%−54,566
First Trust Advisors LP2,507,902$147.3M0.1%+390,856
ARK Investment Management LLC2,295,951$134.8M0.9%−757,867
Wellington Management Group Llp2,274,160$133.6M0.0%−284,125
Geode Capital Management, LLC2,104,000$123.6M0.0%+146,904
Goldman Sachs Group Inc1,642,911$96.5M0.0%+366,651
Fuller & Thaler Asset Management, Inc.1,509,749$88.7M0.2%+95,387
William Blair Investment Management, LLC1,431,596$84.1M0.3%+441,909
Morgan Stanley1,191,790$70.0M0.0%+393,988
Bank Of America Corp /de/1,102,279$64.7M0.0%−346,618
Driehaus Capital Management LLC1,045,826$61.4M0.4%New
Northern Trust Corp996,154$58.5M0.0%+66,654
Charles Schwab Investment Management Inc939,983$55.2M0.0%+16,410
Oberweis Asset Management Inc/877,734$51.5M1.1%+37,900
Legal & General Group Plc858,136$50.4M0.0%−39,035
Sumitomo Mitsui Trust Group, Inc.768,949$45.2M0.0%−286,707
Amova Asset Management Americas, Inc.768,949$45.1M0.6%−276,098
Point72 Asset Management, L.P.737,804$43.3M0.1%+253,900
Fisher Asset Management, LLC700,592$41.1M0.0%−35,678

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

14 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Mar 3, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000+14.6%Report
Nov 12, 2025Gilbert Ray Cisneros, Jr.Democratic, HousePartial sale$1,001 - $15,000+6.7%Report
Jun 16, 2025Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000+40.6%Report
Oct 16, 2023Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000+34.2%Report
Sep 15, 2023Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000−5.3%Report
Apr 10, 2023Daniel S. GoldmanDemocratic, HousePartial sale$1,001 - $15,000−22.5%Report
Dec 23, 2020Gilbert Ray Cisneros, Jr.Democratic, HousePartial sale$1,001 - $15,000+131.1%Report
Dec 10, 2020Gilbert Ray Cisneros, Jr.Democratic, HousePartial sale$1,001 - $15,000+131.8%Report
Dec 8, 2020Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+134.0%Report
Oct 29, 2020Gilbert Ray Cisneros, Jr.Democratic, HousePartial sale$1,001 - $15,000+111.8%Report
Jan 17, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−83.5%Report
Dec 24, 2019Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−88.5%Report
Dec 12, 2019Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−86.4%Report
Dec 6, 2019Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−91.1%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
    Yahoo FinanceVCYT quote
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55